08:00 AM EDT, 06/13/2025 (MT Newswires) -- Astria Therapeutics ( ATXS ) said Friday that initial results from its ongoing long-term open-label trial of navenibart in hereditary angioedema showed a significant reduction in monthly attack rates, supporting the potential for dosing schedules of every three or six months.

The biopharmaceutical company said navenibart demonstrated an overall attack-freedom of 50% over six months. Patients on a three-month dosing regimen achieved 95% mean monthly attack rate reduction while those on a six-month dosing schedule showed 86% average reduction, according to the company.

The company said all 16 patients remain in the study, with no serious side effects or dropouts, reinforcing navenibart's safety and efficacy profile.

Astria said its ongoing pivotal phase 3 trial, which launched last February, is now enrolling patients.

Shares of the company rose more than 12% in recent premarket activity Friday.